abiraterone acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antiandrogens 4176 154229-18-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • abiraterone acetate
  • zytiga
  • CB-7630
  • CB7630
Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor, that inhibits 17 alpha-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis. CYP17 catalyzes two sequential reactions: 1) the conversion of pregnenolone and progesterone to their 17alpha-hydroxy derivatives by 17alpha-hydroxylase activity and 2) the subsequent formation of dehydroepiandrosterone (DHEA) and androstenedione, respectively, by C17,20 lyase activity. DHEA and androstenedione are androgens and are precursors of testosterone. Inhibition of CYP17 by abiraterone can also result in increased mineralocorticoid production by the adrenals. Androgen sensitive prostatic carcinoma responds to treatment that decreases androgen levels. Androgen deprivation therapies, such as treatment with GnRH agonists or orchiectomy, decrease androgen production in the testes but do not affect androgen production by the adrenals or in the tumor. Abiraterone acetate decreased serum testosterone and other androgens in patients in the placebo-controlled clinical trial. It is not necessary to monitor the effect of abiraterone acetate on serum testosterone levels.
  • Molecular weight: 391.56
  • Formula: C26H33NO2
  • CLOGP: 6.11
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 0
  • TPSA: 39.19
  • ALOGS: -5.59
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 g O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 5, 2011 EMA Janssen-Cilag International N.V.
April 28, 2011 FDA JANSSEN BIOTECH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Prostatic specific antigen increased 61.64 41.03 5 80 0 50605039

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 2126.76 15.85 2292 32925 339792 29199518
Prostatic specific antigen increased 2071.75 15.85 715 34502 11849 29527461
Disease progression 748.70 15.85 683 34534 81233 29458077
Therapy cessation 716.89 15.85 348 34869 14114 29525196
Hot flush 579.17 15.85 304 34913 14566 29524744
Hospitalisation 424.12 15.85 386 34831 45602 29493708
Hypokalaemia 423.65 15.85 401 34816 49802 29489508
Metastases to bone 372.90 15.85 198 35019 9700 29529610
Prostate cancer metastatic 350.96 15.85 153 35064 4813 29534497
Osteonecrosis of jaw 263.35 15.85 191 35026 16319 29522991
Fatigue 241.10 15.85 874 34343 315947 29223363
Prostate cancer 187.13 15.85 189 35028 25338 29513972
Malignant neoplasm progression 170.46 15.85 311 34906 73548 29465762
Product size issue 170.09 15.85 51 35166 518 29538792
Urinary tract infection 167.40 15.85 305 34912 72049 29467261
Product use complaint 152.39 15.85 53 35164 891 29538419
Hormone-refractory prostate cancer 144.19 15.85 46 35171 583 29538727
Hospice care 127.72 15.85 78 35139 4990 29534320
Toxicity to various agents 106.54 15.85 37 35180 173624 29365686
Adverse event 106.17 15.85 110 35107 15181 29524129
Prescribed underdose 101.75 15.85 80 35137 7706 29531604
Bone pain 89.26 15.85 110 35107 18342 29520968
Hypertension 87.32 15.85 321 34896 116293 29423017
Completed suicide 87.28 15.85 5 35212 90241 29449069
Incorrect dose administered 83.82 15.85 145 35072 32839 29506471
Blood potassium decreased 76.43 15.85 94 35123 15640 29523670
Therapy interrupted 74.41 15.85 69 35148 8317 29530993
Dysphagia 74.01 15.85 186 35031 54740 29484570
Spinal cord compression 72.48 15.85 48 35169 3534 29535776
Prostatic specific antigen abnormal 68.86 15.85 24 35193 406 29538904
Product dose omission issue 67.68 15.85 260 34957 96123 29443187
Decreased appetite 63.05 15.85 340 34877 145002 29394308
Oedema peripheral 62.87 15.85 267 34950 103290 29436020
Hepatic function abnormal 62.65 15.85 142 35075 39117 29500193
Acquired apparent mineralocorticoid excess 59.65 15.85 13 35204 28 29539282
Urinary tract obstruction 56.80 15.85 40 35177 3257 29536053
Pyrexia 53.84 15.85 170 35047 287452 29251858
Metastases to spine 53.57 15.85 33 35184 2143 29537167
Haematuria 47.88 15.85 138 35079 44001 29495309
Therapy change 45.87 15.85 32 35185 2566 29536744
Blood alkaline phosphatase increased 45.59 15.85 103 35114 28303 29511007
Chemotherapy 45.51 15.85 19 35198 535 29538775
Metastases to liver 45.38 15.85 63 35154 11793 29527517
Asthenia 44.61 15.85 421 34796 214829 29324481
Fluid retention 44.19 15.85 91 35126 23469 29515841
Apparent mineralocorticoid excess 43.27 15.85 10 35207 31 29539279
Drug hypersensitivity 42.87 15.85 14 35203 68392 29470918
Muscular weakness 42.37 15.85 166 35051 61886 29477424
Hydronephrosis 42.13 15.85 52 35165 8678 29530632
Back pain 42.09 15.85 236 34981 102048 29437262
Diabetes mellitus 40.77 15.85 122 35095 39709 29499601
Prostate cancer recurrent 39.29 15.85 20 35197 895 29538415
Oedema 38.64 15.85 121 35096 40362 29498948
Overdose 38.09 15.85 24 35193 79795 29459515
Acute coronary syndrome 37.79 15.85 59 35158 12266 29527044
Wrong technique in product usage process 37.76 15.85 102 35115 31326 29507984
Metastases to lymph nodes 37.48 15.85 34 35183 3983 29535327
Hypotension 36.20 15.85 115 35102 194239 29345071
Metastasis 35.93 15.85 31 35186 3398 29535912
Infusion related reaction 35.56 15.85 5 35212 43881 29495429
Liver function test abnormal 33.88 15.85 93 35124 28825 29510485
Cardiac failure 33.30 15.85 184 35033 79103 29460207
Pruritus 33.19 15.85 55 35162 116794 29422516
Fall 31.56 15.85 336 34881 176842 29362468
Condition aggravated 31.30 15.85 81 35136 146214 29393096
Metabolic acidosis 31.20 15.85 4 35213 37658 29501652
Plasma cell myeloma 30.61 15.85 4 35213 37111 29502199
Blood urine present 30.33 15.85 47 35170 9708 29529602
Prostatic specific antigen decreased 29.70 15.85 9 35208 95 29539215
Peripheral swelling 29.54 15.85 152 35065 63587 29475723
Bone lesion 29.47 15.85 25 35192 2679 29536631
Febrile neutropenia 29.03 15.85 56 35161 112184 29427126
Haemorrhage urinary tract 28.98 15.85 20 35197 1576 29537734
Aggression 28.91 15.85 4 35213 35537 29503773
Wheezing 28.86 15.85 3 35214 33237 29506073
Cystitis 28.70 15.85 42 35175 8250 29531060
Liver disorder 28.39 15.85 85 35132 27664 29511646
Haemorrhage subcutaneous 28.11 15.85 22 35195 2103 29537207
Intentional product misuse 27.96 15.85 4 35213 34657 29504653
Acute biphenotypic leukaemia 27.64 15.85 8 35209 71 29539239
Cardiac disorder 27.32 15.85 102 35115 37161 29502149
Anxiety 27.32 15.85 37 35180 85328 29453982
Asthma 27.09 15.85 4 35213 33845 29505465
Coma 26.67 15.85 7 35210 39443 29499867
Acquired haemophilia 26.57 15.85 15 35202 828 29538482
Agitation 26.50 15.85 14 35203 51290 29488020
Pelvic pain 26.38 15.85 21 35196 2058 29537252
Hypoxia 25.87 15.85 12 35205 47367 29491943
Metastases to soft tissue 25.84 15.85 10 35207 230 29539080
Suicidal ideation 25.80 15.85 5 35212 34711 29504599
Radiotherapy 25.42 15.85 11 35206 339 29538971
Intentional product use issue 24.42 15.85 10 35207 42488 29496822
Hypersensitivity 23.76 15.85 17 35200 52886 29486424
Injection site pain 23.43 15.85 5 35212 32441 29506869
Metastases to lung 23.25 15.85 37 35180 7818 29531492
Adverse drug reaction 23.10 15.85 72 35145 23948 29515362
Constipation 22.93 15.85 222 34995 113938 29425372
Bone cancer metastatic 22.44 15.85 8 35209 145 29539165
Neutropenia 22.40 15.85 81 35136 131630 29407680
Prostate cancer stage IV 21.58 15.85 12 35205 643 29538667
Hepatotoxicity 21.46 15.85 58 35159 17809 29521501
Lactic acidosis 21.16 15.85 5 35212 30242 29509068
Adrenal insufficiency 20.92 15.85 43 35174 11071 29528239
Lymphoedema 20.91 15.85 23 35194 3394 29535916
Oxygen saturation decreased 20.76 15.85 14 35203 44923 29494387
Depressed level of consciousness 20.73 15.85 9 35208 36933 29502377
Mucosal inflammation 20.62 15.85 6 35211 31589 29507721
Bradycardia 20.44 15.85 29 35188 65600 29473710
Staphylococcal infection 20.13 15.85 5 35212 29235 29510075
Retroperitoneal lymphadenopathy 19.97 15.85 12 35205 745 29538565
Anaemia 19.94 15.85 343 34874 200608 29338702
Therapeutic product effect incomplete 19.89 15.85 11 35206 39294 29500016
Blood creatinine increased 19.85 15.85 45 35172 85057 29454253
Hepatic enzyme increased 19.58 15.85 86 35131 33713 29505597
Urosepsis 19.55 15.85 41 35176 10705 29528605
Multiple organ dysfunction syndrome 19.54 15.85 28 35189 63088 29476222
Blood testosterone increased 19.41 15.85 13 35204 975 29538335
Cardio-respiratory arrest 19.35 15.85 19 35198 50582 29488728
Erythema 19.29 15.85 38 35179 75568 29463742
Transaminases increased 19.15 15.85 65 35152 22597 29516713
Rash 19.07 15.85 140 35077 189679 29349631
Drug reaction with eosinophilia and systemic symptoms 18.86 15.85 5 35212 27987 29511323
Coronary artery disease 18.82 15.85 15 35202 44175 29495135
Pollakiuria 18.43 15.85 53 35164 16863 29522447
Urinary retention 18.35 15.85 81 35136 31817 29507493
Sinusitis 18.29 15.85 9 35208 34341 29504969
White blood cell count increased 18.27 15.85 11 35206 37505 29501805
Groin pain 17.62 15.85 25 35192 4773 29534537
Angioedema 17.55 15.85 8 35209 31907 29507403
Alanine aminotransferase increased 17.33 15.85 144 35073 70800 29468510
Fracture 17.21 15.85 28 35189 6025 29533285
Free prostate-specific antigen increased 17.20 15.85 3 35214 0 29539310
Acute kidney injury 17.17 15.85 218 34999 265049 29274261
Tachycardia 17.12 15.85 38 35179 72372 29466938
Tremor 17.06 15.85 39 35178 73499 29465811
Blood creatine phosphokinase increased 17.05 15.85 14 35203 40630 29498680
Neuropathy peripheral 17.02 15.85 37 35180 70990 29468320
Liver function test increased 16.77 15.85 41 35176 11844 29527466
Hip fracture 16.77 15.85 38 35179 10454 29528856
Respiratory arrest 16.69 15.85 5 35212 25828 29513482
Cancer pain 16.49 15.85 17 35200 2330 29536980
Cardiac arrest 16.35 15.85 50 35167 85541 29453769
Investigation 16.09 15.85 11 35206 853 29538457
Hyperglycaemia 16.03 15.85 82 35135 34205 29505105

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Prostatic specific antigen increased 1960.13 16.88 489 23972 8271 64466000
Death 1289.89 16.88 1215 23246 481490 63992781
Disease progression 610.98 16.88 472 23989 141208 64333063
Hot flush 362.49 16.88 223 24238 46012 64428259
Therapy cessation 320.98 16.88 182 24279 32307 64441964
Hypokalaemia 293.66 16.88 292 24169 121611 64352660
Metastases to bone 287.85 16.88 145 24316 20290 64453981
Prostate cancer 268.72 16.88 137 24324 19658 64454613
Prostate cancer metastatic 262.24 16.88 82 24379 3222 64471049
Osteonecrosis of jaw 257.14 16.88 170 24291 39655 64434616
Hospitalisation 176.92 16.88 178 24283 75029 64399242
Fatigue 160.12 16.88 632 23829 748098 63726173
Product size issue 121.29 16.88 31 24430 575 64473696
Hospice care 104.09 16.88 53 24408 7572 64466699
Hormone-refractory prostate cancer 99.43 16.88 24 24437 348 64473923
Malignant neoplasm progression 95.37 16.88 161 24300 112710 64361561
Prescribed underdose 90.59 16.88 66 24395 17949 64456322
Urinary tract infection 90.57 16.88 241 24220 231355 64242916
Incorrect dose administered 78.94 16.88 106 24355 60659 64413612
Haematuria 77.81 16.88 105 24356 60366 64413905
Product use complaint 75.35 16.88 27 24434 1619 64472652
Decreased appetite 75.23 16.88 256 24205 281033 64193238
Toxicity to various agents 73.95 16.88 23 24438 363490 64110781
Completed suicide 66.07 16.88 5 24456 224409 64249862
Blood potassium decreased 62.72 16.88 77 24384 40322 64433949
Oedema peripheral 62.07 16.88 198 24263 210119 64264152
Prostate cancer recurrent 61.25 16.88 19 24442 726 64473545
Apparent mineralocorticoid excess 60.17 16.88 11 24450 34 64474237
Prostatic specific antigen abnormal 57.93 16.88 14 24447 204 64474067
Drug hypersensitivity 56.18 16.88 11 24450 237804 64236467
Metastases to spine 54.66 16.88 27 24434 3616 64470655
Asthenia 51.38 16.88 307 24154 427737 64046534
Cardiac failure 50.89 16.88 137 24324 132236 64342035
Acute coronary syndrome 47.73 16.88 47 24414 19263 64455008
Infusion related reaction 47.46 16.88 4 24457 164463 64309808
Bone pain 47.14 16.88 73 24388 47499 64426772
Urinary tract obstruction 46.48 16.88 25 24436 3992 64470279
Hydronephrosis 45.80 16.88 40 24421 14085 64460186
Hepatic function abnormal 45.58 16.88 85 24376 64228 64410043
Therapy interrupted 44.46 16.88 46 24415 19990 64454281
Acquired apparent mineralocorticoid excess 43.23 16.88 8 24453 27 64474244
Therapy change 42.78 16.88 28 24433 6406 64467865
Muscular weakness 42.29 16.88 125 24336 127213 64347058
Hypersensitivity 38.89 16.88 13 24448 196439 64277832
Product dose omission issue 37.70 16.88 160 24301 194587 64279684
Hypertension 37.04 16.88 195 24266 259066 64215205
Spinal cord compression 35.93 16.88 24 24437 5679 64468592
Haemorrhage urinary tract 35.31 16.88 17 24444 2152 64472119
Rhabdomyolysis 35.30 16.88 95 24366 91631 64382640
Metastases to lymph nodes 35.14 16.88 28 24433 8689 64465582
Arthropathy 34.73 16.88 3 24458 120964 64353307
Metastases to liver 34.54 16.88 44 24417 23897 64450374
Back pain 33.58 16.88 185 24276 249986 64224285
Urinary retention 32.36 16.88 63 24398 49138 64425133
Acute biphenotypic leukaemia 32.06 16.88 8 24453 134 64474137
Sinusitis 31.92 16.88 8 24453 145920 64328351
Constipation 31.72 16.88 171 24290 229166 64245105
Dehydration 31.61 16.88 164 24297 216599 64257672
Radiotherapy 31.51 16.88 10 24451 412 64473859
Blood urine present 30.16 16.88 36 24425 18304 64455967
Condition aggravated 29.16 16.88 61 24400 372365 64101906
Pruritus 29.07 16.88 46 24415 312354 64161917
Myocardial infarction 28.86 16.88 132 24329 165689 64308582
Dysphagia 28.28 16.88 97 24364 106715 64367556
Prostate cancer stage IV 27.82 16.88 10 24451 605 64473666
Metastases to lung 26.82 16.88 31 24430 15233 64459038
Prostatic specific antigen decreased 26.72 16.88 6 24455 62 64474209
Injection site pain 26.61 16.88 5 24456 111403 64362868
Atrial fibrillation 26.01 16.88 131 24330 170958 64303313
Asthma 25.67 16.88 3 24458 95222 64379049
Blood alkaline phosphatase increased 25.49 16.88 62 24399 56217 64418054
Fall 24.73 16.88 254 24207 416572 64057699
Acquired haemophilia 24.28 16.88 12 24449 1608 64472663
General physical health deterioration 24.04 16.88 146 24315 204279 64269992
Metastases to soft tissue 24.03 16.88 8 24453 384 64473887
Anxiety 23.83 16.88 25 24436 202624 64271647
Liver function test abnormal 23.33 16.88 62 24399 59339 64414932
Coma 23.03 16.88 3 24458 87612 64386659
Nasopharyngitis 22.16 16.88 25 24436 196048 64278223
Chemotherapy 22.10 16.88 11 24450 1496 64472775
Pollakiuria 21.50 16.88 41 24420 31489 64442782
Liver disorder 21.27 16.88 56 24405 53295 64420976
Alopecia 21.15 16.88 19 24442 165671 64308600
Diabetes mellitus 20.87 16.88 64 24397 66410 64407861
Wheezing 20.61 16.88 3 24458 80576 64393695
Toxic cataract 20.35 16.88 4 24457 20 64474251
Retroperitoneal lymphadenopathy 20.29 16.88 9 24452 945 64473326
Cancer pain 20.05 16.88 15 24446 4242 64470029
Haemorrhage subcutaneous 19.73 16.88 15 24446 4346 64469925
Oedema 19.71 16.88 78 24383 91857 64382414
Bone lesion 19.64 16.88 16 24445 5121 64469150
Exposure during pregnancy 19.62 16.88 3 24458 77672 64396599
Depressed level of consciousness 18.72 16.88 4 24457 81432 64392839
Blood testosterone increased 18.62 16.88 8 24453 778 64473493
Therapeutic product effect incomplete 18.54 16.88 8 24453 103474 64370797
Overdose 18.41 16.88 20 24441 159546 64314725
Anaemia 18.00 16.88 221 24240 378459 64095812
Urosepsis 17.95 16.88 31 24430 22063 64452208
Intentional product misuse 17.79 16.88 3 24458 72292 64401979
Intentional product use issue 17.69 16.88 7 24454 95357 64378914
Pyrexia 17.54 16.88 132 24329 558512 63915759
Alanine aminotransferase increased 17.42 16.88 101 24360 138930 64335341
Lymphoedema 17.21 16.88 20 24441 9885 64464386
Polyneuropathy in malignant disease 17.12 16.88 5 24456 155 64474116
Wound 17.09 16.88 4 24457 76473 64397798
Rash 17.06 16.88 103 24358 458446 64015825
Blood glucose increased 16.99 16.88 78 24383 97995 64376276

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L02BX03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONE ANTAGONISTS AND RELATED AGENTS
Other hormone antagonists and related agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006727 Hormone Antagonists
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D065088 Steroid Synthesis Inhibitors
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
FDA MoA N0000182632 Cytochrome P450 17A1 Inhibitors
FDA EPC N0000182633 Cytochrome P450 17A1 Inhibitor
FDA MoA N0000187062 Cytochrome P450 2C8 Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:50266 Prodrugs
CHEBI has role CHEBI:68640 17-alpha-hydroxylase/C17,20-lyase inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Malignant tumor of prostate indication 399068003 DOID:10283
Metastatic castration-resistant prostate cancer indication 427492003
Hyperbilirubinemia contraindication 14783006 DOID:2741
Hypertensive disorder contraindication 38341003 DOID:10763
Hypokalemia contraindication 43339004
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Breastfeeding (mother) contraindication 413712001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.68 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
125MG YONSA SUN PHARM N210308 May 22, 2018 RX TABLET ORAL 10292990 May 20, 2034 USE IN COMBINATION WITH METHYLPREDNISOLONE FOR THE TREATMENT OF PATIENTS WITH PROSTATE CANCER

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Steroid 17-alpha-hydroxylase/17,20 lyase Enzyme INHIBITOR IC50 8.54 CHEMBL IUPHAR
Cytochrome P450 3A4 Enzyme IC50 5.57 CHEMBL
Androgen receptor Nuclear hormone receptor EC50 4.77 CHEMBL
Cytochrome P450 11B1, mitochondrial Enzyme IC50 5.79 CHEMBL
Cytochrome P450 11B2, mitochondrial Enzyme IC50 5.76 CHEMBL
Cytochrome P450 17A1 Enzyme IC50 7.90 CHEMBL

External reference:

IDSource
4030721 VUID
N0000182731 NUI
D09701 KEGG_DRUG
4030720 VANDF
4030721 VANDF
C2607886 UMLSCUI
CHEBI:68639 CHEBI
CHEBI:68642 CHEBI
AER PDB_CHEM_ID
CHEMBL271227 ChEMBL_ID
CHEMBL254328 ChEMBL_ID
D000069501 MESH_DESCRIPTOR_UI
9288 IUPHAR_LIGAND_ID
C089740 MESH_SUPPLEMENTAL_RECORD_UI
6745 IUPHAR_LIGAND_ID
154229-19-3 SECONDARY_CAS_RN
EM5OCB9YJ6 UNII
9821849 PUBCHEM_CID
132971 PUBCHEM_CID
DB05812 DRUGBANK_ID
1100071 RXNORM
181225 MMSL
27860 MMSL
299803 MMSL
d07766 MMSL
013720 NDDF
013721 NDDF
699678007 SNOMEDCT_US
699679004 SNOMEDCT_US
767857007 SNOMEDCT_US
C0754011 UMLSCUI
7375 INN_ID
G819A456D0 UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Abiraterone Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0093-1125 TABLET, FILM COATED 250 mg ORAL ANDA 27 sections
Abiraterone HUMAN PRESCRIPTION DRUG LABEL 1 0143-9597 TABLET 250 mg ORAL ANDA 26 sections
Abiraterone Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0378-6920 TABLET 250 mg ORAL ANDA 29 sections
Abiraterone Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0378-6920 TABLET 250 mg ORAL ANDA 29 sections
Abiraterone Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0378-6921 TABLET, FILM COATED 500 mg ORAL ANDA 29 sections
Abiraterone Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0378-6921 TABLET, FILM COATED 500 mg ORAL ANDA 29 sections
Abiraterone Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0378-6924 TABLET, FILM COATED 250 mg ORAL ANDA 29 sections
Abiraterone Acetate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6948 TABLET 250 mg ORAL ANDA 28 sections
Abiraterone Acetate HUMAN PRESCRIPTION DRUG LABEL 1 16714-963 TABLET 250 mg ORAL ANDA 27 sections
Abiraterone Acetate HUMAN PRESCRIPTION DRUG LABEL 1 42291-024 TABLET 250 mg ORAL ANDA 27 sections
ABIRATERONE ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 42291-073 TABLET 500 mg ORAL ANDA 27 sections
Abiraterone Acetate HUMAN PRESCRIPTION DRUG LABEL 1 42292-057 TABLET 250 mg ORAL ANDA 29 sections
Abiraterone Acetate HUMAN PRESCRIPTION DRUG LABEL 1 43598-358 TABLET 250 mg ORAL ANDA 27 sections
YONSA HUMAN PRESCRIPTION DRUG LABEL 1 47335-401 TABLET 125 mg ORAL NDA 28 sections
YONSA HUMAN PRESCRIPTION DRUG LABEL 1 47335-401 TABLET 125 mg ORAL NDA 28 sections
Abiraterone Acetate HUMAN PRESCRIPTION DRUG LABEL 1 51407-181 TABLET 250 mg ORAL ANDA 29 sections
Abiraterone Acetate HUMAN PRESCRIPTION DRUG LABEL 1 51407-181 TABLET 250 mg ORAL ANDA 29 sections
Zytiga HUMAN PRESCRIPTION DRUG LABEL 1 57894-150 TABLET 250 mg ORAL NDA 32 sections
Abiraterone acetate HUMAN PRESCRIPTION DRUG LABEL 1 57894-155 TABLET 250 mg ORAL NDA AUTHORIZED GENERIC 31 sections
Zytiga HUMAN PRESCRIPTION DRUG LABEL 1 57894-195 TABLET, FILM COATED 500 mg ORAL NDA 32 sections
Abiraterone acetate HUMAN PRESCRIPTION DRUG LABEL 1 57894-199 TABLET, FILM COATED 500 mg ORAL NDA 31 sections
Abiraterone Acetate HUMAN PRESCRIPTION DRUG LABEL 1 60505-4327 TABLET 250 mg ORAL ANDA 28 sections
abiraterone acetate HUMAN PRESCRIPTION DRUG LABEL 1 60505-4764 TABLET, FILM COATED 500 mg ORAL ANDA 32 sections
Abiraterone Acetate HUMAN PRESCRIPTION DRUG LABEL 1 60687-455 TABLET 250 mg ORAL ANDA 29 sections
Abiraterone acetate HUMAN PRESCRIPTION DRUG LABEL 1 64679-021 TABLET 250 mg ORAL ANDA 26 sections
Abiraterone acetate Human Prescription Drug Label 1 64980-418 TABLET 250 mg ORAL ANDA 25 sections
Abiraterone HUMAN PRESCRIPTION DRUG LABEL 1 68001-489 TABLET 250 mg ORAL ANDA 25 sections
abiraterone acetate HUMAN PRESCRIPTION DRUG LABEL 1 68462-135 TABLET 250 mg ORAL ANDA 30 sections
abiraterone acetate HUMAN PRESCRIPTION DRUG LABEL 1 68462-135 TABLET 250 mg ORAL ANDA 30 sections
abiraterone acetate HUMAN PRESCRIPTION DRUG LABEL 1 68462-882 TABLET 500 mg ORAL ANDA 30 sections